

## DOPORUČENÁ LITERATURA

1. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd ed. Cephalalgia. 2018;38(1):1–211.
2. Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–76.
3. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. Nat Rev Neurol. 2021;17(8):501–14.
4. Schytz HW, Amin FM, Jensen RH, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd ed. 2020. J Headache Pain. 2021;22(1):22.
5. Lewis DW. Clinician's Manual – Treatment of Pediatric Migraine. 1st ed. Springer Healthcare Tarporley; 2010. Dostupné z: <https://link.springer.com/book/10.1007/978-1-908517-20-3#bibliographic-information>
6. Sacco S, Merki-Feld GS, Ægidius KL, et al; European Headache Federation (EHF), the European Society of Contraception and Reproductive Health (ESCRH). Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). J Headache Pain. 2017;18(1):108.
7. Jakubcová T, Řehulka P. Fatická porucha u migrény s aurou – videokazuistika. Cesk Slov Neurol N. 2021;84/117:486–7.
8. Řehulka P. Palpační vyšetření perikraniální bolestivosti. Bolest. 2022;25:49–52.
9. Řehulka P, Sklenářová B, Bočková K. Den povědomí o cluster headache 2024. Neurologie pro praxi. 2024;25:158–61.

## POUŽITÁ LITERATURA

1. Al-Karagholi MA, Ghanizada H, Nielsen CAW, et al. Opening of ATP sensitive potassium channels causes migraine attacks with aura. *Brain*. 2021;144(8):2322–32. doi: 10.1093/brain/awab136.
2. Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. *Lancet*. 2021;397(10283):1505–18. doi: 10.1016/S0140-6736(20)32342-4.
3. Ashina M, Hansen JM, Á Dunga BO, Olesen J. Human models of migraine - short-term pain for long-term gain. *Nat Rev Neurol*. 2017;13(12):713–24. doi: 10.1038/nrneurol.2017.137.
4. Ashina M, Katsarava Z, Do TP, et al. Migraine: epidemiology and systems of care. *Lancet*. 2021;397(10283):1485–95. doi: 10.1016/S0140-6736(20)32160-7.
5. Ashina M, sdělení v rámci Migraine Preceptorship 2018.
6. Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. *Lancet*. 2021;397(10283):1496–504. doi: 10.1016/S0140-6736(20)32162-0.
7. Ashina M. Migraine. *N Engl J Med*. 2020;383(19):1866–76. doi: 10.1056/NEJMra1915327.
8. Athwal BS, Lennox GG. Acetazolamide responsiveness in familial hemiplegic migraine. *Ann Neurol*. 1996;40(5):820–1. doi: 10.1002/ana.410400526.
9. Bigal ME, Lipton RB. Clinical course in migraine: conceptualizing migraine transformation. *Neurology*. 2008;71(11):848–55. doi: 10.1212/01.wnl.0000325565.63526.d2.
10. Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. *Headache*. 2006;46(9):1334–43. doi: 10.1111/j.1526-4610.2006.00577.x.
11. Burchiel, Kim J. *Surgical Management of Pain*, 2nd ed. Stuttgart: Georg Thieme Verlag KG; 2015.
12. Buse DC, Fanning KM, Reed ML, et al. Life With Migraine: Effects on Relationships, Career, and Finances From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study. *Headache*. 2019;59(8):1286–99. doi: 10.1111/head.13613.
13. Buse DC, Powers SW, Gelfand AA, et al. Adolescent Perspectives on the Burden of a Parent's Migraine: Results from the CaMEO Study. *Headache*. 2018;58(4):512–24. doi: 10.1111/head.13254.
14. Buse DC, Scher AI, Dodick DW, et al. Impact of Migraine on the Family: Perspectives of People With Migraine and Their Spouse/Domestic Partner in the CaMEO Study. *Mayo Clin Proc*. 2016:S0025-6196(16)00126–9. doi: 10.1016/j.mayocp.2016.02.013.

15. Diener HC, Dodick DW, Aurora SK, et al.; PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. *Cephalalgia*. 2010;30(7):804–14. doi: 10.1177/0333102410364677.
16. Diener HC, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. *Clinical and Translational Neuroscience*. 2019;3(1). doi:10.1177/2514183X18823377.
17. Do TP, Guo S, Ashina M. Therapeutic novelties in migraine: new drugs, new hope? *J Headache Pain*. 2019;20(1):37. doi: 10.1186/s10194-019-0974-3. Erratum in: *J Headache Pain*. 2019;20(1):55.
18. Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. *Cephalalgia*. 2019;39(3):445–58. doi:10.1177/0333102418821662
19. Edvinsson L, Linde M. New drugs in migraine treatment and prophylaxis: telcagepant and topiramate. *Lancet*. 2010;376(9741):645–55. doi: 10.1016/S0140-6736(10)60323-6.
20. Edvinsson L, sdělení na 12th European Headache Federation Congress 2019.
21. Eigenbrodt AK, Ashina H, Khan S, et al. Diagnosis and management of migraine in ten steps. *Nat Rev Neurol*. 2021;17(8):501–14. doi: 10.1038/s41582-021-00509-5.
22. Evans RW, Linder SL. Management of basilar migraine. *Headache*. 2002;42(5):383–4. doi: 10.1046/j.1526-4610.2002.02113.x.
23. Evers S. Non-Invasive Neurostimulation Methods for Acute and Preventive Migraine Treatment-A Narrative Review. *J Clin Med*. 2021;10(15):3302. doi: 10.3390/jcm10153302.
24. Gaillard F, Yap J, Smith D, et al. Chiari I malformation. Reference article (on 26 Oct 2022), Radiopaedia.org (Accessed on 02 Aug 2023) <https://doi.org/10.53347/rID-1111>
25. GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet Neurol*. 2018;17(11):954–76. doi: 10.1016/S1474-4422(18)30322-3. Erratum in: *Lancet Neurol*. 2021;20(12):e7.
26. Genc H, Baykan B, Bolay H, et al.; Head-MENAA study group. Cross-sectional, hospital-based analysis of headache types using ICHD-3 criteria in the Middle East, Asia, and Africa: the Head-MENAA study. *J Headache Pain*. 2023;24(1):24. doi: 10.1186/s10194-023-01555-8.
27. Grundy SM, Cleeman JI, Daniels SR, et al.; American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*. 2005;112(17):2735–52. doi: 10.1161/CIRCULATIONAHA.105.169404. Erratum in: *Circulation*. 2005;112(17):e297. Erratum in: *Circulation*. 2005;112(17):e298.
28. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd ed. *Cephalalgia*. 2018;38(1):1–211. doi: 10.1177/0333102417738202.

29. Herrero Babiloni A, Nixdorf DR, Moana-Filho EJ. Persistent dentoalveolar pain disorder: A putative intraoral chronic overlapping pain condition. *Oral Dis.* 2020;26(8):1601–09. doi: 10.1111/odi.13248.
30. Hoffmann J, Mollan SP, Paemeleire K, et al. European headache federation guideline on idiopathic intracranial hypertension. *J Headache Pain.* 2018;19(1):93. doi: 10.1186/s10194-018-0919-2.
31. <https://usti.nempk.cz/labdocs/oun-okbd/HVEZDALATI.htm>
32. Israel H, Neeb L, Reuter U. CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine. *Curr Pain Headache Rep.* 2018;22(5):38. doi: 10.1007/s11916-018-0686-4.
33. Katsarava Z, Buse DC, Manack AN, Lipton RB. Defining the differences between episodic migraine and chronic migraine. *Curr Pain Headache Rep.* 2012;16(1):86–92. doi: 10.1007/s11916-011-0233-z.
34. Labastida-Ramírez A, Rubio-Beltrán E, Villalón CM, MaassenVanDenBrink A. Gender aspects of CGRP in migraine. *Cephalalgia.* 2019;39(3):435–44. doi: 10.1177/0333102417739584.
35. Lewis DW. *Clinician's Manual – Treatment of Pediatric Migraine.* 1st ed. Springer Healthcare Tarporley; 2010. Dostupné z: [https:// link.springer.com/book/10.1007/978-1-908517-20-3#bibliographic-information](https://link.springer.com/book/10.1007/978-1-908517-20-3#bibliographic-information).
36. Linde M, Gustavsson A, Stovner LJ, et al. The cost of headache disorders in Europe: the Eurolight project. *Eur J Neurol.* 2012;19(5):703–11. doi: 10.1111/j.1468-1331.2011.03612.x.
37. Lipton RB, Bigal ME, Kolodner K, et al. The family impact of migraine: population-based studies in the USA and UK. *Cephalalgia.* 2003;23(6):429–40. doi: 10.1046/j.1468-2982.2003.00543.x.
38. Mathew NT, Frishberg BM, Gawel M, et al.; BOTOX CDH Study Group. Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. *Headache.* 2005;45(4):293–307. doi: 10.1111/j.1526-4610.2005.05066.x.
39. Meadows J, Kraut M, Guarnieri M, et al. Asymptomatic Chiari Type I malformations identified on magnetic resonance imaging. *J Neurosurg.* 2000;92(6):920–6. doi: 10.3171/jns.2000.92.6.0920.
40. Messlinger K, Fischer MJ, Lennerz JK. Neuropeptide effects in the trigeminal system: pathophysiology and clinical relevance in migraine. *Keio J Med.* 2011;60(3):82–9. doi: 10.2302/kjm.60.82.
41. Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. *J Neurol Neurosurg Psychiatry.* 2018;89(10):1088–100. doi: 10.1136/jnnp-2017-317440.
42. Nežádal T, Marková J, Bártková A, Klečka L. CGRP monoklonální protilátky v léčbě migrény – indikační kritéria a terapeutická doporučení pro Českou republiku. *Cesk Slov Neurol N.* 2020;83/116(4): 445–51. doi: 10.14735/am-csnn2020445.
43. Olesen J, Burstein R, Ashina M, Tfelt-Hansen P. Origin of pain in migraine: evidence for peripheral sensitisation. *Lancet Neurol.* 2009;8(7):679–90. doi: 10.1016/S1474-4422(09)70090-0.

44. Předpis č. 359/2009 Sb., zdroj: SBÍRKA ZÁKONŮ ročník 2009, částka 113, ze dne 20. 10. 2009.
45. Racek J, Rajdl D. Klinická biochemie. Praha: Galén; 2006.
46. Russell MB, Olesen J. A nosographic analysis of the migraine aura in a general population. *Brain*. 1996;119 ( Pt 2):355–61. doi: 10.1093/brain/119.2.355.
47. Sacco S, Braschinsky M, Ducros A, et al. European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). *J Headache Pain*. 2020;21(1):76. doi: 10.1186/s10194-020-01130-5.
48. Sacco S, Merki-Feld GS, Ægidius KL, et al.; European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). *J Headache Pain*. 2017;18(1):108. doi: 10.1186/s10194-017-0815-1. Erratum in: *J Headache Pain*. 2018;19(1):81.
49. Scrivani SJ, Graff-Radford SB, Khawaja SN, Spierings ELH. Headache. In: Farah C, Balasubramaniam R, McCullough M. (eds) *Contemporary Oral Medicine*. Springer, Cham; 2017. [https://doi.org/10.1007/978-3-319-28100-1\\_33-1](https://doi.org/10.1007/978-3-319-28100-1_33-1)
50. Schmidt-Hansen PT, Svensson P, Bendtsen L, et al. Increased muscle pain sensitivity in patients with tension-type headache. *Pain*. 2007;129(1-2):113–21. doi: 10.1016/j.pain.2006.09.037.
51. Schytz HW, Amin FM, Jensen RH, et al. Reference programme: diagnosis and treatment of headache disorders and facial pain. Danish Headache Society, 3rd ed., 2020. *J Headache Pain*. 2021;22(1):22. doi: 10.1186/s10194-021-01228-4.
52. Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the Eurolight project. *J Headache Pain*. 2014;15(1):31. doi: 10.1186/1129-2377-15-31.
53. Steiner TJ, Stovner LJ, Nichols E, et al. Headache in the Global Burden of Disease (GBD) studies. In: Steiner TJ, Stovner LJ (eds). *Societal impact of headache*. 1st ed. Basel: Springer Nature Switzerland AG. 2019. p. 105–26.
54. Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. *J Headache Pain*. 2022;23(1):34. doi: 10.1186/s10194-022-01402-2.
55. Suchopár J, Suchopár Š, Prokeš M. Lékové interakce antimigrenik (2. část). *Remedia*. 2021;31:391–97.
56. Tassorelli C, Jensen R, Allena M, et al.; the COMOESTAS Consortium. A consensus protocol for the management of medication-overuse headache: Evaluation in a multicentric, multinational study. *Cephalalgia*. 2014;34(9):645–55. doi: 10.1177/0333102414521508.
57. Turner DP, Houle TT. Psychological evaluation of a primary headache patient. *Pain Manag*. 2013;3(1):19–25. doi: 10.2217/pmt.12.77.
58. Vinciguerra L, Cantone M, Lanza G, et al. Migrainous Infarction And Cerebral Vasospasm: Case Report And Literature Review. *J Pain Res*. 2019;12:2941–50. doi: 10.2147/JPR.S209485.

59. White TG, Powell K, Shah KA, et al. Trigeminal Nerve Control of Cerebral Blood Flow: A Brief Review. *Front Neurosci.* 2021;15:649910. doi: 10.3389/fnins.2021.649910.
60. Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. *Neurology.* 2003;60(1):120–1. doi: 10.1212/01.wnl.0000042051.16284.70.
61. Yunus MB. Editorial review: an update on central sensitivity syndromes and the issues of nosology and psychobiology. *Curr Rheumatol Rev.* 2015;11(2):70–85. doi: 10.2174/157339711102150702112236.